As required under applicable securities laws, the BAR contains the following financial statements and related notes thereto:
- Audited combined and carve-out financial statements of
CBI Home Health as at and for the year endedDecember 31, 2025 , together with the independent auditor’s report thereon; and - Unaudited pro forma consolidated financial statements of the Company, including the unaudited pro forma consolidated statement of financial position of the Company for the year ended
December 31, 2025 and the unaudited pro forma consolidated statement of earnings of the Company for the year endedDecember 31, 2025 .
Pro Forma Fiscal 2025 Financial Highlights
As reflected in the unaudited pro forma consolidated financial statements of the Company included in the BAR:
- Extendicare’s pro forma consolidated revenue for the year ended
December 31, 2025 is$2.164 billion , including$504.0 million of CBI Home Health’s standalone revenue. This compares to the approximately$477.9 million standalone revenue ofCBI Home Health for the twelve-month period endingJuly 31, 2025 previously reported by the Company in its management’s discussion and analysis for the year endedDecember 31, 2025 (the “2025 MD&A”). - Extendicare’s pro forma consolidated Adjusted EBITDA(1) for the year ended
December 31, 2025 is$263.5 million , including$87.9 million of CBI Home Health’s standalone Adjusted EBITDA. Included in CBI Home Health’s standalone Adjusted EBITDA for the year endedDecember 31, 2025 are out-of-period items totalling approximately$15.0 million related to retroactive funding amounts and workers’ compensation rebates. These amounts relate to prior periods and are not reflective of CBI Home Health’s actual results for the year endedDecember 31, 2025 . Additionally, as previously reported in the 2025 MD&A, the Company identified certain adjustments related to differences in estimates and timing matters identified by the Company’s Quality of Earnings (“QoE”) due diligence of$3.3 million . Excluding the out-of-period items and including the QoE adjustments, CBI Home Health’s standalone Adjusted EBITDA for the year endedDecember 31, 2025 was$69.6 million , as compared to the$61.9 million for the twelve-months endedJuly 31, 2025 previously reported in the 2025 MD&A.
About
Non-GAAP Measures
“Adjusted EBITDA” is not a measure recognized under GAAP and does not have a standardized meaning prescribed by GAAP. This measure may differ from similar computations as reported by other issuers and, accordingly, may not be comparable to similarly titled measures as reported by such issuers. This measure is not intended to replace earnings (loss) from continuing operations, net earnings (loss), cash flow, or other measures of financial performance and liquidity reported in accordance with GAAP. Such items are presented in this document because management believes that they are relevant measures of Extendicare’s and CBI Home Health’s operating performance and the Company’s ability to pay cash dividends.
Management uses these measures to exclude the impact of certain items, because it believes doing so provides investors a more effective analysis of underlying operating and financial performance and improves comparability of underlying financial performance between periods. The exclusion of certain items does not imply that they are non-recurring or not useful to investors.
Detailed descriptions of this measure can be found in Extendicare’s Q1 2026 MD&A (refer to “Non-GAAP Measures”), which is available on SEDAR+ at www.sedarplus.ca and on Extendicare’s website at www.extendicare.com.
T: (905) 470-4000
E: david.bacon@extendicare.com
www.extendicare.com
| Endnote | ||
| (1) | See the “Non-GAAP Measures” section of this press release and the Company’s Q1 2026 MD&A, which includes the reconciliation of such non-GAAP measure to the most directly comparable GAAP measure. | |

![]()
2026 GlobeNewswire, Inc., source

















